OBJECTIVE: The etiology of Parkinson disease (PD) is complex and multifactorial, with hereditary and environmental factors contributing. Monogenic forms have provided molecular clues to disease mechanisms but genetic modifiers of idiopathic PD are still to be determined. METHODS: We carried out whole-genome expression profiling of isolated human substantia nigra (SN) neurons from patients with PD vs. controls followed by association analysis of tagging single-nucleotide polymorphisms (SNPs) in differentially regulated genes. Association was investigated in a German PD sample and confirmed in Italian and British cohorts. RESULTS: We identified four differentially expressed genes located in PD candidate pathways, ie, MTND2 (mitochondrial, p = 7.14 x 10(-7)), PDXK (vitamin B6/dopamine metabolism, p = 3.27 x 10(-6)), SRGAP3 (axon guidance, p = 5.65 x 10(-6)), and TRAPPC4 (vesicle transport, p = 5.81 x 10(-6)). We identified a DNA variant (rs2010795) in PDXK associated with an increased risk of PD in the German cohort (p = 0.00032). This association was confirmed in the British (p = 0.028) and Italian (p = 0.0025) cohorts individually and reached a combined value of p = 1.2 x 10(-7) (odds ratio [OR], 1.3; 95% confidence interval [CI], 1.18-1.44). INTERPRETATION: We provide an example of how microgenomic genome-wide expression studies in combination with association analysis can aid to identify genetic modifiers in neurodegenerative disorders. The detection of a genetic variant in PDXK, together with evidence accumulating from clinical studies, emphasize the impact of vitamin B6 status and metabolism on disease risk and therapy in PD.
OBJECTIVE: The etiology of Parkinson disease (PD) is complex and multifactorial, with hereditary and environmental factors contributing. Monogenic forms have provided molecular clues to disease mechanisms but genetic modifiers of idiopathic PD are still to be determined. METHODS: We carried out whole-genome expression profiling of isolated human substantia nigra (SN) neurons from patients with PD vs. controls followed by association analysis of tagging single-nucleotide polymorphisms (SNPs) in differentially regulated genes. Association was investigated in a German PD sample and confirmed in Italian and British cohorts. RESULTS: We identified four differentially expressed genes located in PD candidate pathways, ie, MTND2 (mitochondrial, p = 7.14 x 10(-7)), PDXK (vitamin B6/dopamine metabolism, p = 3.27 x 10(-6)), SRGAP3 (axon guidance, p = 5.65 x 10(-6)), and TRAPPC4 (vesicle transport, p = 5.81 x 10(-6)). We identified a DNA variant (rs2010795) in PDXK associated with an increased risk of PD in the German cohort (p = 0.00032). This association was confirmed in the British (p = 0.028) and Italian (p = 0.0025) cohorts individually and reached a combined value of p = 1.2 x 10(-7) (odds ratio [OR], 1.3; 95% confidence interval [CI], 1.18-1.44). INTERPRETATION: We provide an example of how microgenomic genome-wide expression studies in combination with association analysis can aid to identify genetic modifiers in neurodegenerative disorders. The detection of a genetic variant in PDXK, together with evidence accumulating from clinical studies, emphasize the impact of vitamin B6 status and metabolism on disease risk and therapy in PD.
Authors: Demetrius M Maraganore; Mariza de Andrade; Timothy G Lesnick; Kari J Strain; Matthew J Farrer; Walter A Rocca; P V Krishna Pant; Kelly A Frazer; David R Cox; Dennis G Ballinger Journal: Am J Hum Genet Date: 2005-09-09 Impact factor: 11.025
Authors: Michael Krawczak; Susanna Nikolaus; Huberta von Eberstein; Peter J P Croucher; Nour Eddine El Mokhtari; Stefan Schreiber Journal: Community Genet Date: 2006
Authors: J L Eberling; W J Jagust; C W Christine; P Starr; P Larson; K S Bankiewicz; M J Aminoff Journal: Neurology Date: 2008-04-09 Impact factor: 9.910
Authors: Andreas Bender; Kim J Krishnan; Christopher M Morris; Geoffrey A Taylor; Amy K Reeve; Robert H Perry; Evelyn Jaros; Joshua S Hersheson; Joanne Betts; Thomas Klopstock; Robert W Taylor; Douglass M Turnbull Journal: Nat Genet Date: 2006-04-09 Impact factor: 38.330
Authors: David C Glahn; Joanne E Curran; Anderson M Winkler; Melanie A Carless; Jack W Kent; Jac C Charlesworth; Matthew P Johnson; Harald H H Göring; Shelley A Cole; Thomas D Dyer; Eric K Moses; Rene L Olvera; Peter Kochunov; Ravi Duggirala; Peter T Fox; Laura Almasy; John Blangero Journal: Biol Psychiatry Date: 2011-10-07 Impact factor: 13.382
Authors: Anna C Cummings; Stephen L Lee; Jacob L McCauley; Lan Jiang; Amy Crunk; Lynne L McFarland; Paul J Gallins; Denise Fuzzell; Clare Knebusch; Charles E Jackson; William K Scott; Margaret A Pericak-Vance; Jonathan L Haines Journal: Ann Hum Genet Date: 2011-05 Impact factor: 1.670
Authors: Nicole J Van Bergen; Yiran Guo; Noraldin Al-Deri; Zhanna Lipatova; Daniela Stanga; Sarah Zhao; Rakhilya Murtazina; Valeriya Gyurkovska; Davut Pehlivan; Tadahiro Mitani; Alper Gezdirici; Jayne Antony; Felicity Collins; Mary J H Willis; Zeynep H Coban Akdemir; Pengfei Liu; Jaya Punetha; Jill V Hunter; Shalini N Jhangiani; Jawid M Fatih; Jill A Rosenfeld; Jennifer E Posey; Richard A Gibbs; Ender Karaca; Sean Massey; Thisara G Ranasinghe; Patrick Sleiman; Chris Troedson; James R Lupski; Michael Sacher; Nava Segev; Hakon Hakonarson; John Christodoulou Journal: Brain Date: 2020-01-01 Impact factor: 13.501
Authors: Manfred Gerlach; Walter Maetzler; Karl Broich; Harald Hampel; Lucas Rems; Torsten Reum; Peter Riederer; Albrecht Stöffler; Johannes Streffer; Daniela Berg Journal: J Neural Transm (Vienna) Date: 2011-07-14 Impact factor: 3.575
Authors: Nicole K A Wilson; Yohan Lee; Robert Long; Karen Hermetz; M Katharine Rudd; Rachel Miller; Judith L Rapoport; Anjené M Addington Journal: Case Rep Genet Date: 2011-09-12